血管紧张素Ⅱ治疗与难治性血管扩张性休克ARDS患者氧合改善相关
该研究为ATHOS-3试验的事后亚组分析,纳入符合改良柏林ARDS标准的81例患者,其中34例(42%)随机接受血管紧张素Ⅱ、47例(58%)接受安慰剂。主要终点为校正基线P:F后48小时的P:F,血管紧张素Ⅱ组由基线155 mmHg(SD 69)升至48小时265 mmHg(SD 160),安慰剂组无变化(148 mmHg(SD 63)至164 mmHg(SD 74)),基线校正差值+98.4 mmHg(95%CI 35.2-161.5),p=0.0028。氧合指数、3小时持续血流动力学应答率亦有改善,PEEP、分钟通气量、通气比值无差异。作者认为这为血管紧张素Ⅱ治疗ARDS合并血管扩张性休克提供了生理学依据。
要点
- ATHOS-3事后分析纳入81例改良柏林标准ARDS患者,血管紧张素Ⅱ组48小时P:F由155 mmHg升至265 mmHg,安慰剂组148 mmHg至164 mmHg,基线校正差值+98.4 mmHg(95%CI 35.2-161.5),p=0.0028。
- 氧合指数血管紧张素Ⅱ组48小时下降-6.0 cmH2O/mmHg,安慰剂组-0.4 cmH2O/mmHg,基线校正差值-4.8 cmH2O/mmHg(95%CI -8.6至-1.1),p=0.0273。
- 3小时持续血流动力学应答血管紧张素Ⅱ组22例(64.7%)vs安慰剂组17例(36.2%),绝对风险差28.5%(95%CI 6.5-47.0%),p=0.0120。
- PEEP、分钟通气量、通气比值两组无差异;第7天存活且脱机血管紧张素Ⅱ组7/34(20.6%)vs安慰剂组5/47(10.6%),第28天死亡率55.9% vs 68.1%。
- 作者认为该生理学依据支持开展血管紧张素Ⅱ治疗ARDS合并血管扩张性休克的试验。
适用人群与场景
- ATHOS-3试验中入组时符合改良柏林ARDS标准、合并儿茶酚胺难治性血管扩张性休克的患者,共81例。
诊断标准与关键阈值
- 入组时符合改良柏林ARDS标准。
研究设计与关键结果
- 研究类型:ATHOS-3(Angiotensin Therapy for High Output Shock)试验的事后亚组分析。
- 81例ARDS患者中34例(42%)随机至血管紧张素Ⅱ、47例(58%)随机至安慰剂。
- 主要终点48小时P:F:血管紧张素Ⅱ组由基线155 mmHg(SD 69)升至265 mmHg(SD 160),安慰剂组148 mmHg(SD 63)至164 mmHg(SD 74),基线校正差值+98.4 mmHg(95%CI 35.2-161.5),p=0.0028。
- 氧合指数48小时变化:血管紧张素Ⅱ组-6.0 cmH2O/mmHg vs安慰剂组-0.4 cmH2O/mmHg,基线校正差值-4.8 cmH2O/mmHg(95%CI -8.6至-1.1),p=0.0273。
- 3小时持续血流动力学应答:血管紧张素Ⅱ组22例(64.7%)vs安慰剂组17例(36.2%),绝对风险差28.5%(95%CI 6.5-47.0%),p=0.0120。
- 第7天存活且脱机:血管紧张素Ⅱ组7/34(20.6%)vs安慰剂组5/47(10.6%)。
- 第28天死亡率:血管紧张素Ⅱ组55.9% vs安慰剂组68.1%。
- PEEP、分钟通气量、通气比值两组无差异。
证据类型、等级与局限
- 证据类型:随机对照试验的事后亚组分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现为血管紧张素Ⅱ作为ARDS合并血管扩张性休克治疗的试验提供了生理学依据。
指南或共识出处
- Angiotensin Therapy for High Output Shock(ATHOS-3)试验,ClinicalTrials.Gov注册号NCT02338843(注册日期2015年1月14日)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The physiological effects of renin-angiotensin system modulation in acute respiratory distress syndrome (ARDS) remain controversial and have not been investigated in randomized trials. We sought to determine whether angiotensin-II treatment is associated with improved oxygenation in shock-associated ARDS.
METHODS: Post-hoc subgroup analysis of the Angiotensin Therapy for High Output Shock (ATHOS-3) trial. We studied patients who met modified Berlin ARDS criteria at enrollment. The primary outcome was PaO2/FiO2-ratio (P:F) at 48-h adjusted for baseline P:F. Secondary outcomes included oxygenation index, ventilatory ratio, PEEP, minute-ventilation, hemodynamic measures, patients alive and ventilator-free by day-7, and mortality.
RESULTS: Of 81 ARDS patients, 34 (42%) and 47 (58%) were randomized to angiotensin-II or placebo, respectively. In angiotensin-II patients, mean P:F increased from 155 mmHg (SD: 69) at baseline to 265 mmHg (SD: 160) at hour-48 compared with no change with placebo (148 mmHg (SD: 63) at baseline versus 164 mmHg (SD: 74) at hour-48)(baseline-adjusted difference: + 98.4 mmHg [95%CI 35.2-161.5], p = 0.0028). Similarly, oxygenation index decreased by - 6.0 cmH2O/mmHg at hour-48 with angiotensin-II versus - 0.4 cmH2O/mmHg with placebo (baseline-adjusted difference: -4.8 cmH2O/mmHg, [95%CI - 8.6 to - 1.1], p = 0.0273). There was no difference in PEEP, minute ventilation, or ventilatory ratio. Twenty-two (64.7%) angiotensin-II patients had sustained hemodynamic response to treatment at hour-3 versus 17 (36.2%) placebo patients (absolute risk-difference: 28.5% [95%CI 6.5-47.0%], p = 0.0120). At day-7, 7/34 (20.6%) angiotensin-II patients were alive and ventilator-free versus 5/47(10.6%) placebo patients. Day-28 mortality was 55.9% in the angiotensin-II group versus 68.1% in the placebo group.
CONCLUSIONS: In post-hoc analysis of the ATHOS-3 trial, angiotensin-II was associated with improved oxygenation versus placebo among patients with ARDS and catecholamine-refractory vasodilatory shock. These findings provide a physiologic rationale for trials of angiotensin-II as treatment for ARDS with vasodilatory shock.
TRIAL REGISTRATION: ClinicalTrials.Gov Identifier: NCT02338843 (Registered January 14th 2015).
参考来源
- Leisman DE, Handisides DR, Chawla LS, et al. Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock. Ann Intensive Care. 2023. PMID: 38103056. doi:10.1186/s13613-023-01227-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。